同期根治性膀胱切除与肾输尿管切除术治疗同时性或异时性全尿路上皮癌患者的肿瘤学与肾功能结局
回顾性分析1996至2017年67例因全尿路上皮癌接受同期根治性膀胱切除与单侧肾输尿管切除术的患者,中位随访38个月,5年总生存率44%、癌症特异性生存率61%;术前61.2%患者eGFR<60 mL/min,术后升至83.5%,29.8%需肾脏替代治疗;结论认为肿瘤学与功能结局均不佳。
要点
- 同期手术患者5年总生存率仅44%,约4成存活。
- 术后83.5%患者eGFR<60 mL/min,29.8%需肾脏替代治疗。
- 约三分之一患者在18个月内出现尿道或对侧肾复发。
核心结论
- 全尿路上皮癌患者接受同期手术的肿瘤学结局不佳,5年时仅约4成存活,功能结局亦不佳,约3分之1术后需肾脏替代治疗。
研究设计与样本
- 回顾性分析1996年至2017年67例因全尿路上皮癌接受同期根治性膀胱切除与单侧肾输尿管切除术的患者,采用Kaplan-Meier法估计残留尿路上皮无复发生存、无转移生存、总生存和癌症特异性生存,并构建Cox多因素模型。
主要发现
- 中位随访38个月,29.8%患者出现复发,34.3%出现转移,67.2%患者因任何原因死亡,37.3%死于尿路上皮癌。
- 5年总生存率和癌症特异性生存率分别为44%和61%。
- 多因素分析中,术前进展为肌层浸润性膀胱癌、根治性膀胱切除和或肾输尿管切除时存在肌层浸润分期、前列腺尿道受累为无转移生存和癌症特异性生存较差的预测因素。
- 术前41例(61.2%)eGFR<60 mL/min,术后升至56例(83.5%);29.8%患者术后需要肾脏功能替代治疗(16例血液透析和4例肾移植)。
临床怎么用
- 作者认为高达3分之1的患者在18个月内出现复发(尿道或对侧肾),支持密切监测或考虑预防性尿道切除。
- 作者认为这些数据有助于对患者进行疾病负担和预期寿命的咨询。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess clinical outcomes of patients who underwent simultaneous radical cystectomy (RC) and radical nephroureterectomy (RNU) for panurothelial carcinoma (PanUC). MATERIALS AND METHODS: A retrospective analysis of 67 patients who underwent simultaneous RC and unilateral RNU for PanUC, from 1996 to 2017. Kaplan-Meier estimates for remnant urothelium recurrence-free survival, metastasis-free survival, overall survival (OS), and cancer-specific survival (CSS) were performed. Cox multivariate models were constructed. RESULTS: The median follow-up was 38 months, 29.8% of patients had a recurrence, 34.3% had metastasis, 67.2% of patients died from any cause, and 37.3% died from urothelial carcinoma. Overall survival and CSS rates at 5 years were 44% and 61%, respectively. In multivariate analysis, progression to muscle-invasive bladder cancer before surgery, presence of muscle-invasive stages at RC and/or RNU, and prostatic urethra involvement were predictors for worse metastasis-free survival and CSS. Forty-one patients (61.2%) had an estimated glomerular filtration rate (eGFR) <60 mL/min before surgery and the number rose to 56 (83.5%) after surgery; 29.8% patients needed renal function replacement therapy after surgery (16 haemodialysis and 4 renal transplant). CONCLUSION: Patients with PanUC who undergo simultaneous surgery have adverse oncological (only 4 out of every 10 remain alive at 5 years) and functional outcomes (1 out of 3 will need renal function replacement therapy after surgery). Up to a third of the patients had a recurrence (urethra or contralateral kidney) within 18 months, justifying close surveillance or considering prophylactic urethrectomy. These data should help in counsel on morbidity and life expectancy.
引用
- Subiela JD, González-Padilla DA, Huguet J, et al. Oncological and Renal Function Outcomes in Patients Who Underwent Simultaneous Radical Cystectomy and Nephroureterectomy for Synchronous or Metachronous Panurothelial Carcinoma. Urology. 2022. PMID: 36436672. doi:10.1016/j.urology.2022.08.064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。